Provides readers with a framework to understand and analyze several medicine pricing policies. Through case studies from countries across geographies and income tiers, this book explores the challenges and opportunities related to price control experiences. Studying global policies this book discusses approaches, strategies, and the underlying pharmaceutical pricing practices used to provide advice for formulating highly effective policies. Alongside the cases, this book covers appropriate research methods for pricing analysis, the essential components of pricing policy, data quality, and the generic structure of a pharmaceutical pricing policy.
1. Chapter 1. Pharmaceutical pricing policies: introduction, key concepts, and evidence synthesis - p. 1 2. Chapter 2. Analysis of antiretroviral medicines prices - p. 15 3. Chapter 3. Evidence on pharmaceutical pricing policies in Europe - p. 37 4. Chapter 4. Pharmaceutical pricing policies in Italy - p. 59 5. Chapter 5. Pharmaceutical pricing policies in Indonesia - p. 75 6. Chapter 6. Canada’s medicine pricing policies: strategies and challenges in a complex federation - p. 105 7. Chapter 7. Pharmaceutical pricing policies in Thailand - p. 125 8. Chapter 8. Pharmaceutical pricing policies in China: an evidence synthesis analysis - p. 141 9. Chapter 9. Strategies for medicine pricing in Southeast Asia - p. 157 10. Chapter 10. Pharmaceutical pricing policies in Syria - p. 177 11. Chapter 11. Pharmaceutical pricing policies in Finland—an example of uptake of less expensive biologic medicines - p. 191 12. Chapter 12. Citizens’ voices in pharmaceutical pricing and reimbursement - p. 209 13. Chapter 13. Pharmaceutical pricing policies in Spain - p. 227 14. Chapter 14. Pharmaceutical pricing strategies in the United States - p. 243 15. Chapter 15. Money matters—how financing affects medicines R&D - p. 261 16. Chapter 16. The role of civil society organizations in ensuring price transparency - p. 275 17. Chapter 17. How to price advanced therapies? Mixed approach for valuing a new CAR-T cell for multiple myeloma in Brazil - p. 293 18. Chapter 18. Pharmaceutical pricing policies in Greece - p. 317 19. Index - p. 337
Provides readers with a framework to understand and analyze several medicine pricing policies. Through case studies from countries across geographies and income tiers, this book explores the challenges and opportunities related to price control experiences. Studying global policies this book discusses approaches, strategies, and the underlying pharmaceutical pricing practices used to provide advice for formulating highly effective policies. Alongside the cases, this book covers appropriate research methods for pricing analysis, the essential components of pricing policy, data quality, and the generic structure of a pharmaceutical pricing policy.
1. Chapter 1. Pharmaceutical pricing policies: introduction, key concepts, and evidence synthesis - p. 1 2. Chapter 2. Analysis of antiretroviral medicines prices - p. 15 3. Chapter 3. Evidence on pharmaceutical pricing policies in Europe - p. 37 4. Chapter 4. Pharmaceutical pricing policies in Italy - p. 59 5. Chapter 5. Pharmaceutical pricing policies in Indonesia - p. 75 6. Chapter 6. Canada’s medicine pricing policies: strategies and challenges in a complex federation - p. 105 7. Chapter 7. Pharmaceutical pricing policies in Thailand - p. 125 8. Chapter 8. Pharmaceutical pricing policies in China: an evidence synthesis analysis - p. 141 9. Chapter 9. Strategies for medicine pricing in Southeast Asia - p. 157 10. Chapter 10. Pharmaceutical pricing policies in Syria - p. 177 11. Chapter 11. Pharmaceutical pricing policies in Finland—an example of uptake of less expensive biologic medicines - p. 191 12. Chapter 12. Citizens’ voices in pharmaceutical pricing and reimbursement - p. 209 13. Chapter 13. Pharmaceutical pricing policies in Spain - p. 227 14. Chapter 14. Pharmaceutical pricing strategies in the United States - p. 243 15. Chapter 15. Money matters—how financing affects medicines R&D - p. 261 16. Chapter 16. The role of civil society organizations in ensuring price transparency - p. 275 17. Chapter 17. How to price advanced therapies? Mixed approach for valuing a new CAR-T cell for multiple myeloma in Brazil - p. 293 18. Chapter 18. Pharmaceutical pricing policies in Greece - p. 317 19. Index - p. 337
